A Phase 2 Pharmacodynamic Trial of Ezogabine (Retigabine) on Neuronal Excitability in Amyotrophic Lateral Sclerosis

Trial Profile

A Phase 2 Pharmacodynamic Trial of Ezogabine (Retigabine) on Neuronal Excitability in Amyotrophic Lateral Sclerosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Retigabine (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Dec 2016 Time frame of Primary endpoint has been changed from Screening, Baseline, Week 4, Week 6, Week 8, Week 12 to Screening, Baseline, Week 6, Week 8.
    • 22 Dec 2016 Planned End Date changed from 1 May 2017 to 1 Feb 2018.
    • 22 Dec 2016 Planned primary completion date changed from 1 May 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top